Cardiology

Top Story

FDA approves ticagrelor for long-term use after ACS event

September 3, 2015

AstraZeneca announced that a 60 mg twice-daily dose of its antiplatelet agent ticagrelor has been approved by the FDA for prevention of CV death, MI and stroke in patients more than 1 year after an ACS event.

Ticagrelor (Brilinta) was previously approved in a 90 mg twice-daily dose for use in patients up to 1 year after an ACS event for prevention of CV events and stent thrombosis, according to an AstraZeneca press release.

Meeting News Coverage

Early, sensitive troponin I assessment safe, effective for acute MI diagnosis

September 3, 2015
LONDON — A new algorithm incorporating a more sensitive cutoff for troponin I values to identify non-STEMI would result in lower mortality and allow more rapid…
Pamela S. Douglas, MD Meeting News CoveragePerspective

PLATFORM: FFR-CT reduces unnecessary invasive catheterization in patients with suspected CAD

September 3, 2015
LONDON — Patients with suspected CAD planned for invasive catheterization were less likely to undergo an unnecessary procedure if their diagnosis was guided by CTA…
VIDEO: Five IMPROVE-IT analyses indicate safety, efficacy of ezetimibe Meeting News CoverageVideo

VIDEO: Five IMPROVE-IT analyses indicate safety, efficacy of ezetimibe

September 3, 2015
LONDON — In this video, Robert P. Giugliano, MD, a cardiologist at Brigham and Women's Hospital and senior investigator with the TIMI Study Group, discusses…
In the Journals

Calorie restriction could improve health outcomes related to aging

September 3, 2015
A 12% restriction in calories among average or slightly overweight individuals improved risk factors for age related diseases, as well as influenced blood pressure…
More News Headlines »
CME
Cardiology Case Consults

The Patient with Obesity

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with obesity.
More »
Meeting News Coverage Video
VIDEO: ARTS-HF results indicate benefits of finerenone for certain patients with HF

VIDEO: ARTS-HF results indicate benefits of finerenone for certain patients with HF

September 2, 2015
LONDON — In this video, Richard A. Chazal, MD, FACC, medical director of the Heart and Vascular Institute at Lee…
More »
CME
Highlights from Lipid Forum 2015™: Focus on Hypertriglyceridemia

Highlights from Lipid Forum 2015®: Focus on Hypertriglyceridemia

This activity is supported by an educational grant from AstraZeneca.

Hypertriglyceridemia is a highly prevalent yet modifiable risk factor for atherosclerotic disease, pancreatitis, and…
More »
morganatic-roan
morganatic-roan